Vaccines for covid-19 patients
If you want to see all comparisons, please click here
BNT162b2 vs Placebo
Forest plots were updated on January 8th, 2021.The Evidence profile and Summary of Findings table were updated on January 25th, 2021.
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04368728 BioNTech/Fosun Pharma/Pfizer Polack F, N Engl J Med, 2020 Full text Commentary ; Commentary ; Commentary ; Commentary ; Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 2/3 | Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA | N=43448 |
Some concerns Details |
|
The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.
The risk of bias by domain as well as overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.